Compare HCAT & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | PYPD |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 85.1M |
| IPO Year | 2019 | 2014 |
| Metric | HCAT | PYPD |
|---|---|---|
| Price | $2.26 | $5.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $2.53 | ★ $12.25 |
| AVG Volume (30 Days) | ★ 1.6M | 226.9K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.48 | N/A |
| 52 Week Low | $0.96 | $3.06 |
| 52 Week High | $4.12 | $5.62 |
| Indicator | HCAT | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 57.47 |
| Support Level | $2.23 | $4.22 |
| Resistance Level | $2.35 | $5.62 |
| Average True Range (ATR) | 0.14 | 0.36 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 74.00 | 64.36 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.